The association of aromatic amino acids with coronary artery disease and major adverse cardiovascular events in a Chinese population

被引:0
|
作者
Mu, Hongna [1 ]
Wang, Xinyue [2 ,3 ]
Yang, Ruiyue [1 ]
Wang, Siming [1 ]
Zhang, Wenduo [2 ,3 ]
Li, Hongxia [1 ]
Ji, Fusui [2 ,3 ]
Chen, Wenxiang [4 ]
Dong, Jun [1 ]
Yu, Xue [2 ,3 ]
机构
[1] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol Natl Hlth Commiss, Key Lab Geriatr,Beijing Inst Geriatr,Inst Geriatr, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Dept Cardiol, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Inst Geriatr Med, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Natl Ctr Clin Labs,Inst Geriatr Med, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金; 国家重点研发计划;
关键词
Coronary artery disease; aromatic amino acids; phenylalanine; tyrosine; tryptophan; major adverse cardiovascular events; TRYPTOPHAN; MORTALITY; ATHEROSCLEROSIS; RISK;
D O I
10.1080/09637486.2024.2405095
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study aimed to evaluate the relationship between aromatic amino acids (AAAs), - phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp) - and coronary artery disease (CAD) in a prospective study involving 2970 participants undergoing coronary angiography at Beijing Hospital. Serum levels of Phe, Tyr and Trp were analysed. The cross-sectional data revealed that serum Tyr and Trp levels were significantly and inversely associated with CAD. During a median follow-up period of 44 months, 343 major adverse cardiovascular events (MACEs) and 138 all-cause deaths were recorded. MACE included myocardial infarction, stroke, revascularisation and all-cause mortality. Low serum Trp levels predicted an increased risk of MACE and death. High serum Phe levels were linked to an increased risk of MACE, while low Tyr levels were associated with a higher risk of death. Collectively, our findings underscore a close correlation between AAAs and CAD, as well as their potential predictive value for adverse cardiovascular outcomes.
引用
收藏
页码:825 / 834
页数:10
相关论文
共 50 条
  • [1] Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease
    Meyersohn, Nandini M.
    Mayrhofer, Thomas
    Corey, Kathleen E.
    Bittner, Daniel O.
    Staziaki, Pedro V.
    Szilveszter, Balint
    Hallett, Travis
    Lu, Michael T.
    Puchner, Stefan B.
    Simon, Tracey G.
    Foldyna, Borek
    Voora, Deepak
    Ginsburg, Geoffrey S.
    Douglas, Pamela S.
    Hoffmann, Udo
    Ferencik, Maros
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (07) : 1480 - +
  • [2] Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease
    Berger, Ariel
    Simpson, Alex
    Bhagnani, Tarun
    Leeper, Nicholas J.
    Murphy, Brian
    Nordstrom, Beth
    Ting, Windsor
    Zhao, Qi
    Berger, Jeffrey S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 123 (12): : 1893 - 1899
  • [3] Prospective association of a genetic risk score with major adverse cardiovascular events in patients with coronary artery disease
    Zhao, Chen
    Zhu, Pin
    Shen, Qile
    Jin, Li
    MEDICINE, 2017, 96 (51)
  • [4] Insights into the reporting of major adverse cardiovascular events in coronary artery disease trials
    Lee, E.
    Tan, B.
    Chin, Y. H.
    Chan, Y. H.
    Ong, J.
    Goh, R. S. J.
    Chong, B.
    Anand, V. V.
    Kong, G.
    Wang, J. W.
    Muthiah, M. D.
    Loh, P. H.
    Chan, M. Y.
    Chew, N. W. S.
    Mamas, M. A.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [5] The Association between Major Adverse Cardiovascular Events and Peripheral Artery Disease Burden
    Niiranen, Oskari
    Virtanen, Juha
    Rantasalo, Ville
    Ibrahim, Amer
    Venermo, Maarit
    Hakovirta, Harri
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2024, 11 (06)
  • [6] Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
    Zhou, Xiao-hong
    Cai, Li-yun
    Lai, Wei-Hua
    Bai, Xue
    Liu, Yi-bin
    Zhu, Qian
    He, Guo-dong
    Chen, Ji-Yan
    Huang, Min
    Zhou, Zhi-ling
    Zhong, Shi-long
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [7] IMPACT OF COMORBID CORONARY ARTERY DISEASE AND SEVERE PERIPHERAL ARTERY DISEASE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS
    Ting, Windsor
    Zhao, Qi
    Haskell, Lloyd
    Lurie, Fedor
    Berger, Jeffrey
    Eapen, Zubin
    Valko, Matthew
    Alas, Veronica
    Rich, Kelly
    Crivera, Concetta
    Schein, Jeff
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1390 - 1390
  • [8] Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease
    von Haehling, Stephan
    Papassotiriou, Jana
    Morgenthaler, Nils G.
    Hartmann, Oliver
    Doehner, Wolfram
    Stellos, Konstantinos
    Wurster, Thomas
    Schuster, Andreas
    Nagel, Eike
    Gawaz, Meinrad
    Bigalke, Boris
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 162 (01) : 27 - 32
  • [9] Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease
    Wheeler, Matt
    Chan, Noel
    Eikelboom, John
    FUTURE CARDIOLOGY, 2020, 16 (06) : 597 - 612
  • [10] Progression of coronary artery calcium density and major adverse cardiovascular events
    Meng, Qingchao
    Zhao, Li
    Zhao, Na
    An, Yunqiang
    Lu, Bin
    Gao, Yang
    ATHEROSCLEROSIS, 2024, 398